一種以DNA為基礎(chǔ)的尿液檢測能夠檢測膀胱細(xì)胞的基因改變，其敏感度幾乎是傳統(tǒng)尿液細(xì)胞學(xué)檢測的2倍，傳統(tǒng)方法作為血尿患者的初始診斷檢查。

UroVysion是由Abbott分子學(xué)(Des Plaines, IL, USA)公司開發(fā)的，使用DNA探針鑒別與膀胱癌相聯(lián)系的4種染色體異常。UroVysion又叫做“分子細(xì)胞學(xué)”因為它能夠同時檢測傳統(tǒng)細(xì)胞學(xué)的形態(tài)學(xué)細(xì)胞改變，以及分子DNA改變。

作為當(dāng)前診斷方法的輔助手段，該技術(shù)既能夠檢測染色體病變，幫助臨床醫(yī)生監(jiān)測既往診斷為膀胱癌患者的復(fù)發(fā)情況，同時可以作為疑似膀胱癌血尿患者的初始診斷檢查。UroVysion是根據(jù)Abbott公司熒光原位雜交(FISH)技術(shù)而研發(fā)的，已經(jīng)獲得了美國食品藥品管理局的批準(zhǔn)。
 
DNA Urine Test Diagnoses Bladder Cancer
 
A DNA-based urine test that detects genetic changes in bladder cells has almost twice the sensitivity of conventional urine cytology tests for the initial diagnosis of bladder cancer in patients with hematuria (blood in urine).

UroVysion, which was developed by Abbott Molecular (Des Plaines, IL, USA), uses DNA probes to identify up to four chromosomal abnormalities frequently associated with bladder cancer. UroVysion is also known as “molecular cytology” because it assesses both morphologic cellular changes of conventional cytology and molecular DNA changes.

Intended as an aid to current diagnostic procedures, its ability to detect chromosomal change can provide deeper insight to the clinician in monitoring for tumor recurrence in patients previously diagnosed with bladder cancer, and in the initial diagnosis in patients with hematuria suspected of having bladder cancer. UroVysion is based on Abbott's proprietary fluorescence in situ hybridization (FISH) technology and has been approved by the U.S. Food and Drug Association (FDA).